CDT Equity Inc. (CDT)
NasdaqCM: CDT
· Real-Time Price · USD
2.92
-0.23 (-7.30%)
At close: Aug 14, 2026, 3:58 PM
2.92
+0.00%
After-hours: 7:34 PM
CDT Equity Inc. (CDT) Stock Price, Analysis & Data
-7.30% (1D)
| Bid | 2.16 |
| Market Cap | 2.3M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.53M |
| Beta | 1.49 |
| EPS (ttm) | -81.6 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -0.04 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2025 |
| Ask | 3.58 |
| Volume | 28,093 |
| Avg. Volume (20D) | 730,648 |
| Open | 2.97 |
| Previous Close | 3.15 |
| Day's Range | 2.80 - 3.08 |
| 52-Week Range | 2.53 - 3460.00 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CDT
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, wh...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 28, 2022
Employees 4
Stock Exchange NasdaqCM
Ticker Symbol CDT
Website https://www.cdtequity.com
Financial Performance
In 2025, CDT Equity's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -39.22M, an increase of 120.33%.
Financial StatementsCDT Equity Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
